GlaxoSmithKline (United Kingdom)-ko ikertzaileekin lankidetzan egindako argitalpenak (1)

2022

  1. Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 9, pp. 2367-2374.e3